© Rosalind Scientific LLC 2018-2022
© Rosalind Scientific LLC, 2018-2022
New Drug Hunter content, featured events and job postings straight to your inbox. Trusted by >3,500 drug hunters worldwide, unsubscribe anytime.
<< Back to November
oral picomolar & reversible CDK7 inhibitor
Ph. I candidate in breast cancer comb. Therapy
from previous CDK7 inhibitor SY-1365
Journal of Medicinal Chemistry
Syros Pharmaceuticals Inc.
4. The Syros Pharmaceuticals CDK7 kinase inhibitor, SY-5609, is a picomolar, reversible, and highly selective molecule with slow off-rate kinetics. It follows a prior covalent clinical candidate from Syros. The…
Ask your company or librarian about a Drug Hunter membership to to see all summaries and get access to even more helpful information.